The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
about
Vaccines for preventing typhoid feverVaccines for preventing typhoid feverA mouse model of Salmonella typhi infectionA mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; expanding the use of Vi polysaccharide vaccine in southeast China: a cluster-randomized trialEntirely Carbohydrate-Based Vaccines: An Emerging Field for Specific and Selective Immune ResponsesThe Burden of Typhoid and Paratyphoid in India: Systematic Review and Meta-analysisRevisiting typhoid fever surveillance in low and middle income countries: lessons from systematic literature review of population-based longitudinal studiesThe case for a typhoid vaccine probe study and overview of design elementsVaccines against invasive Salmonella disease: current status and future directionsComplex adaptive immunity to enteric fevers in humans: lessons learned and the path forwardEpidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella InfectionsGlobal trends in typhoid and paratyphoid FeverRethinking typhoid fever vaccines: implications for travelers and people living in highly endemic areasDevelopment of a bead immunoassay to measure Vi polysaccharide-specific serum IgG after vaccination with the Salmonella enterica serovar Typhi Vi polysaccharideTemporal fluctuation of multidrug resistant salmonella typhi haplotypes in the mekong river delta region of VietnamPopulation-based incidence of typhoid fever in an urban informal settlement and a rural area in Kenya: implications for typhoid vaccine use in AfricaIncidence of typhoid bacteremia in infants and young children in southern coastal PakistanSafety, immunogenicity and dose ranging of a new Vi-CRM₁₉₇ conjugate vaccine against typhoid fever: randomized clinical testing in healthy adultsSalmonella typhi Genomics: Envisaging the Future of Typhoid Eradication.Enteric infections, diarrhea, and their impact on function and development.Part I. Analysis of data gaps pertaining to Salmonella enterica serotype Typhi infections in low and medium human development index countries, 1984-2005.A study of typhoid fever in five Asian countries: disease burden and implications for controls.Salmonella enterica serovar typhimurium trxA mutants are protective against virulent challenge and induce less inflammation than the live-attenuated vaccine strain SL3261.Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugatesSynthetic {beta}-(1->6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogensImmunization with recombinantly expressed glycan antigens from Schistosoma mansoni induces glycan-specific antibodies against the parasite.Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings.Re-examination of immune response and estimation of anti-Vi IgG protective threshold against typhoid fever-based on the efficacy trial of Vi conjugate in young childrenActive immunization in the United States: developments over the past decade.Construction, genotypic and phenotypic characterization, and immunogenicity of attenuated DeltaguaBA Salmonella enterica serovar Typhi strain CVD 915.Characterization of anti-Salmonella enterica serotype Typhi antibody responses in bacteremic Bangladeshi patients by an immunoaffinity proteomics-based technologyCell-associated flagella enhance the protection conferred by mucosally-administered attenuated Salmonella Paratyphi A vaccines.Intranasal immunization strategy to impede pilin-mediated binding of Pseudomonas aeruginosa to airway epithelial cellsVi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.Invasive non-typhoidal salmonella disease: an emerging and neglected tropical disease in Africa.Do CD1-restricted T cells contribute to antibody-mediated immunity against Mycobacterium tuberculosis?Development of Vi conjugate - a new generation of typhoid vaccine.Updated recommendations for the use of typhoid vaccine--Advisory Committee on Immunization Practices, United States, 2015.Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O polysaccharide-flagellin glycoconjugates.Prevention and self-treatment of traveler's diarrhea.
P2860
Q24201238-9DB69AD5-723F-4655-B139-DBDDABC937B4Q24244406-7A388F4F-C71F-486B-8330-77840266292BQ24610761-C15A66CA-7D7E-43D7-B1D6-E5ED52D6D331Q24811133-7B0CDE7A-3C83-415E-A159-5855475EB598Q26746887-3849B28E-91EC-4DE6-A6D7-B1823620F31BQ26747650-1338B49F-A0C0-4E18-A0A0-16001114881BQ26773033-938F2E64-EBE1-4DCC-A7A6-A0EB15CE2687Q26859432-89C5CAD9-8704-4E2D-A52F-0BA06CBD1D8CQ27007088-CE75BCF7-3D7B-409B-8A8B-671B6B886E51Q27694492-CB6962DC-4A6E-4F8E-A4B2-ABC926E34FA5Q28084595-B443D5C6-2B20-4CC7-B2EF-85C994C2F43CQ28267865-E8569760-EF79-455C-86FA-987AB8714946Q28308143-9AF54CF1-B212-4A1D-B093-6101BEDE71C4Q28394220-AAFCA06F-D2EB-4DD2-A91F-5D0D164606DFQ28476687-141665ED-4363-4D24-B45D-E25E581D5A90Q28478975-0D49283D-1753-4DE2-B93F-3423D9413A6AQ28741285-487FF590-4B81-40BD-BD23-B52B53689163Q28744376-2A95596E-1A41-46A5-96F3-B8C8F448425FQ30234360-5789D561-345F-4B9E-A93F-756770E6BB6EQ30443288-57C07A0B-CCE8-4CB1-B632-A33E84AA489EQ31121277-264BB01B-F56B-4EFD-A6CD-950B0345DACAQ33330938-0E0B8EFC-B805-4071-AF6B-5F31A982C0A4Q33557755-9F589BC8-BE20-425B-A2D1-41D45ED0C0F3Q33613531-6173C1A5-EDE4-4A54-B7F3-54C1AE86AD48Q33613913-1ACDBC5D-8790-4788-A156-FCA36E512FD5Q33684607-9F16D9D6-CCB3-4C3A-BC20-CF7EA8A95205Q33773373-5C1B9EAD-C1B5-4D98-9A7A-C0990FB54CD2Q33797264-7D949345-FAF0-44CF-BB8D-700A26231129Q33975799-CF465873-754F-4AC3-8247-5C5AAA5EE6AEQ34008449-2BCC0686-4ABA-4F74-99F7-D9B2DD04AFD2Q34044935-35C80D02-88EA-4E05-82CF-902EBA473902Q34070619-9F1E7094-B4F9-4802-8F3D-15D1556F91E9Q34111774-8BA838A1-64CA-48CD-9A63-720D5FEF62F8Q34179527-6CE877BF-4406-4771-8A1A-E7FE7B5AF958Q34275116-E7BD9711-6346-4657-ACAF-03471C8ABCF8Q34334259-EAF6FCD8-C52B-4E97-A444-08683230248CQ34380025-BEC38F65-1852-4429-BE94-F4E3028FD6D6Q34468771-D213335E-3FB4-49A6-8ABC-3899038359AFQ34760675-C9BA9353-EC50-4F3D-B349-8C5E89AE9246Q34974972-79FEED0D-046F-4851-9D78-8898F774CA4F
P2860
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
@ast
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
@en
type
label
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
@ast
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
@en
prefLabel
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
@ast
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
@en
P2093
P1476
The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children.
@en
P2093
Kossaczka Z
Robbins JB
Schneerson R
Shiloach J
P304
P356
10.1056/NEJM200104263441701
P407
P577
2001-04-01T00:00:00Z